Neoplasms

Respiratory Tract (Lung and Bronchial) Diseases

All Conditions

Carcinoma, Non-Small-Cell Lung

Lung Neoplasms

Carcinoma

Respiratory Tract Neoplasms

Thoracic Neoplasms

Lung Diseases

Respiratory Tract Diseases

Carcinoma, Bronchogenic

Bronchial Neoplasms

Antineoplastic Agents

All Drugs and Chemicals

Amino Acids

Carboplatin

Vinorelbine

Erlotinib Hydrochloride

Tyrosine Kinase Inhibitors

Protein Kinase Inhibitors

Enzyme Inhibitors

Tubulin Modulators

Antimitotic Agents

Tyrosine

Erlotinib

Vinorelbine 25 mg/m2, i.v., day 1 and 8 of every cycle (21 days) plus carboplatin AUC 5, i.v., day 1 of every cycle

Vinorelbine and Carboplatin

Heinrich, Dr.

Bonnet, Dr.

Alexander Schmittel, Dr.

Monika Serke, Dr.

Sylke Kurz, Dr.

Meinolf Karthaus, Prof. Dr.

Meinolf Karthaus, Prof. dr.

Yon-Dschun Ko, Prof. Dr.

Raack, Dr.

Gerd Höffken, Prof. Dr.

Wolfram Meister, Dr.

Norbert Meidenbauer, Dr.

Michael Schroeder, Dr.

Schütte, Prof. Dr.

Eberhardt, Dr.

Koester, Prof. Dr.

Elke Jäger, Prof. Dr.

von Pawel, Dr.

Tessen, Dr.

Ralf Ewert, Prof. Dr.

Martin Reck, Dr.

Schüttrumpf, Dr.

Kaukel, Prof. Dr.

Nicolas Dickgreber, Dr.

Michael Thomas, Prof. Dr.

Lutz Freitag, Dr.

Andreas Göschel, Dr.

Angelika Reißig, Dr.

Martin Wolf, Prof. Dr.

Michael von Eiff, Prof. Dr.

Niederle, Prof. Dr.

Fischer, Dr.

Dalhoff, Prof. Dr.

Kortsik, Prof. Dr.

Dieter Buchheidt, Dr.

Bodenstein, Prof. Dr.

Huber, Prof. Dr.

Deppermann, Dr.

Steffi Mai, Dr.

Stefan Schumann, Dr.

Stefan Krüger, Dr.

60% of all malignant diseases occur in patients who are 65 years or older. For these patients, aggressive treatments are often not suitable due to reduced life-expectancy, reduced general condition, comorbidities, and reduced vital functions which can lead to increased adverse effects of chemotherapy. Therefore, it is important to investigate alternative therapy options for elderly patients.

Erlotinib is an orally applied medication which is associated with reasonable toxicity. This targeted agent may prove an effective and well-tolerated first-line therapy in elderly patients with advanced non small cell lung cancer.

Therefore, the aim of this study is to investigate the progression-free survival of the combination of vinorelbine and carboplatin in comparison to erlotinib. Given that there will be no significant reduction of efficiency this may provide elderly patients of more than 70 years of age with an active oral substance without subjecting them to the sometimes severe adverse effect of the chemotherapy.

Erlotinib Versus Carboplatin/Vinorelbine in Elderly Patients With Advanced Non-Small Cell Lung Cancer (NSCLC)

Multicentre Randomised Phase II Trial of Erlotinib Versus Carboplatin/Vinorelbine in Elderly Patients (=/> 70 Years) With Advanced Non-Small Cell Lung Cancer

LungenClinic Grosshansdorf

Dr. Martin Reck

Study title	NCT ID	Conditions	Interventions	Eligibility	Organization	Link
Erlotinib Versus Carboplatin/Vinorelbine in Elderly Patients With Advanced Non-Small Cell Lung Cancer (NSCLC)	NCT00678964	Non-Small Cell ...	Erlotinib Vinorelbine and...	70 Years -	LungenClinic Grosshansdorf
Erlotinib Versus Carboplatin/Vinorelbine in Elderly Patients With Advanced Non-Small Cell Lung Cancer (NSCLC)	NCT00678964	Non-Small Cell ...	Erlotinib Vinorelbine and...	70 Years -	LungenClinic Grosshansdorf

Spots Global Cancer Trial Database for vinorelbine and carboplatin